Synthetic peptide corresponding to the N-termal extracellular domain of human vasopressin V2 receptor. The immunizing peptide has 67% homology with the rat and mouse gene.
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Immunohistochemistry (1 paper)
Biochem/physiol Actions
Vasopressin V2 receptor is a G-protein-coupled receptor that binds to the peptide hormone arginine vasopressin produced by posterior pituitary gland. The V2 receptor stimulates the production of cyclic AMP, controls the water reabsorption and salt balance by the kidneys. Antagonists to the V2 receptor have applications in the treatment of congestive heart failure, hypertension, hyponatremia and excessive water retention.
Physical form
Solution in phosphate buffered saline containing 0.1% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Experimental and therapeutic medicine, 21(6), 566-566 (2021-04-15)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced disease. Desmopressin (dDAVP) is a widely used blood-saving agent that
Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and
[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V(4)Q(5)]dDAVP inhibits angiogenesis and metastatic progression
International journal of molecular sciences, 23(14) (2022-07-28)
Vasopressin type-2 receptor (V2R) is ectopically expressed and plays a pathogenic role in clear cell renal cell carcinoma (ccRCC) tumor cells. Here we examined how V2R signaling within human ccRCC tumor cells (Caki1 cells) stimulates stromal cancer-associated fibroblasts (CAFs). We
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.